171 related articles for article (PubMed ID: 26422573)
1. Early detection of colon cancer by increased serum level of Krebs von den Lungen-6 in a patient with dermatomyositis-associated interstitial pneumonia.
Fukuhara N; Tanino Y; Sato S; Fukuhara A; Uematsu M; Nikaido T; Misa K; Sato Y; Saito J; Wang X; Munakata M
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):265-70. PubMed ID: 26422573
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
3. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
5. Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis.
Isoda K; Kotani T; Takeuchi T; Konma J; Ishida T; Hata K; Otani K; Fujiwara H; Shoda T; Makino S; Arawaka S
Clin Respir J; 2018 Jul; 12(7):2235-2241. PubMed ID: 29633527
[TBL] [Abstract][Full Text] [Related]
6. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis.
Arai S; Kurasawa K; Maezawa R; Owada T; Okada H; Fukuda T
Mod Rheumatol; 2013 Sep; 23(5):872-83. PubMed ID: 22983659
[TBL] [Abstract][Full Text] [Related]
7. [Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren's syndrome: a case report].
Yu JF; Jin YB; He J; An Y; Li ZG
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):910-914. PubMed ID: 29045979
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
[TBL] [Abstract][Full Text] [Related]
9. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis.
Bandoh S; Fujita J; Ohtsuki Y; Ueda Y; Hojo S; Tokuda M; Dobashi H; Kurata N; Yoshinouchi T; Kohno N; Takahara J
Ann Rheum Dis; 2000 Apr; 59(4):257-62. PubMed ID: 10733471
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemical Analysis of Krebs von den Lungen-6 (KL-6) Expression in Lung Tissue in Primary Lung Cancer Patients with High Serum KL-6 Levels].
Yatsuyanagi E; Sato K; Sato K
Kyobu Geka; 2015 Sep; 68(10):815-9. PubMed ID: 26329623
[TBL] [Abstract][Full Text] [Related]
11. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
[TBL] [Abstract][Full Text] [Related]
12. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.
Fathi M; Barbasso Helmers S; Lundberg IE
J Intern Med; 2012 Jun; 271(6):589-97. PubMed ID: 21950266
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
Takanashi S; Nishina N; Nakazawa M; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2019 Jun; 58(6):1034-1039. PubMed ID: 30624752
[TBL] [Abstract][Full Text] [Related]
14. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
Ma H; Lu J; Song Y; Wang H; Yin S
BMC Pulm Med; 2020 Jan; 20(1):6. PubMed ID: 31915006
[TBL] [Abstract][Full Text] [Related]
15. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases.
Nakajima H; Harigai M; Hara M; Hakoda M; Tokuda H; Sakai F; Kamatani N; Kashiwazaki S
J Rheumatol; 2000 May; 27(5):1164-70. PubMed ID: 10813282
[TBL] [Abstract][Full Text] [Related]
16. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study.
Oguz EO; Kucuksahin O; Turgay M; Yildizgoren MT; Ates A; Demir N; Kumbasar OO; Kinikli G; Duzgun N
Clin Rheumatol; 2016 Mar; 35(3):663-6. PubMed ID: 26758437
[TBL] [Abstract][Full Text] [Related]
17. Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review.
Wang Y; Chen S; Lin Z; Lin J; Xie X; Lin Q; Du G; Huang X; Matucci-Cerinic M; Furst DE
Clin Rheumatol; 2019 May; 38(5):1433-1436. PubMed ID: 30746580
[TBL] [Abstract][Full Text] [Related]
18. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease.
Gono T; Masui K; Nishina N; Kawaguchi Y; Kawakami A; Ikeda K; Kirino Y; Sugiyama Y; Tanino Y; Nunokawa T; Kaneko Y; Sato S; Asakawa K; Ukichi T; Kaieda S; Naniwa T; Okano Y; Kuwana M;
Arthritis Rheumatol; 2021 Apr; 73(4):677-686. PubMed ID: 33118321
[TBL] [Abstract][Full Text] [Related]
19. KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker.
Hanaoka M; Katsumata Y; Kawasumi H; Kawaguchi Y; Yamanaka H
Mod Rheumatol; 2019 Jul; 29(4):625-632. PubMed ID: 30484723
[No Abstract] [Full Text] [Related]
20. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
